A Study of YZJ-4729 Tartrate Injection for the Treatment of Pain After Abdominal Surgery

Launched by SHANGHAI HAIYAN PHARMACEUTICAL TECHNOLOGY CO., LTD. · Mar 21, 2025

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Be able to understand the study purpose and cooperate with the study procedures of this trial, voluntarily provide written informed consent
• • 2. Body mass index (BMI) ≥18 kg/m2 and ≤28 kg/m2.
• • 3. ASA I - II
• • 4. Experiences a pain intensity rating of moderate to severe acute pain following abdominal surgery, with a pain intensity score of ≥4 on a Numeric Rating Scale (NRS) within 4 hours post-surgery
• Exclusion Criteria:
• • 1. Allergy to opioids and other medications that may be used during the trial.
• • 2. Nervous system disorders (e.g. epilepsy)
• • 3. Psychiatric disorders (e.g. depression)
• • 4. History of difficult airways
• • 5. Random blood glucose ≥11.1 mmol/L
• • 6. Uncontrolled blood pressure \[e.g., hypertension (systolic blood pressure ≥160 mmHg, diastolic blood pressure ≥100 mmHg)，or hypotension(systolic blood pressure \<90 mmHg)\]
• • 7. Abnormal pulse oxygen saturation (SpO2 \<90 %)
• • 8. Abnormal liver function or renal function
• • 9. Used agents that could affect the analgesic response
• • 10. Used agents that could affect drug metabolism
• • 11. Has previously participated in another YZJ-4729 clinical study